Fibrinolytic Variables in Patients with Recurrent Venous Thrombosis: a Prospective Cohort Study

Mark A. Crowther; Jeremy Roberts; Robin Roberts; Marilyn Johnston; Pamela Stevens; Peter Skingley; G. M. Patrassi; M. T. Sartori; Jack Hirsh; Paolo Prandoni; Jeffrey I. Weitz; Michael Gent; Jeffrey S. Ginsberg

doi:10.1055/s-0037-1615594

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2001; 85(03): 390-394
DOI: 10.1055/s-0037-1615594

Rapid Communications

Schattauer GmbH

Fibrinolytic Variables in Patients with Recurrent Venous Thrombosis: a Prospective Cohort Study

Mark A. Crowther

¹Hamilton Civic Hospitals Research Centre, Henderson General Hospital, Hamilton, ON, Canada

³McMaster University, Department of Medicine

⁵St Joseph’s Hospital, Hamilton, ON, Canada

,

Jeremy Roberts

¹Hamilton Civic Hospitals Research Centre, Henderson General Hospital, Hamilton, ON, Canada

,

Robin Roberts

¹Hamilton Civic Hospitals Research Centre, Henderson General Hospital, Hamilton, ON, Canada

⁴McMaster University, Department of Clinical Epidemiology and Biostatistics

,

Marilyn Johnston

¹Hamilton Civic Hospitals Research Centre, Henderson General Hospital, Hamilton, ON, Canada

,

Pamela Stevens

¹Hamilton Civic Hospitals Research Centre, Henderson General Hospital, Hamilton, ON, Canada

,

Peter Skingley

¹Hamilton Civic Hospitals Research Centre, Henderson General Hospital, Hamilton, ON, Canada

⁴McMaster University, Department of Clinical Epidemiology and Biostatistics

,

G. M. Patrassi

²Institute of Medical Semeiotics, University of Padua Medical School; Padua, Italy

,

M. T. Sartori

²Institute of Medical Semeiotics, University of Padua Medical School; Padua, Italy

,

Jack Hirsh

¹Hamilton Civic Hospitals Research Centre, Henderson General Hospital, Hamilton, ON, Canada

³McMaster University, Department of Medicine

,

Paolo Prandoni

²Institute of Medical Semeiotics, University of Padua Medical School; Padua, Italy

,

Jeffrey I. Weitz

¹Hamilton Civic Hospitals Research Centre, Henderson General Hospital, Hamilton, ON, Canada

³McMaster University, Department of Medicine

,

Michael Gent

¹Hamilton Civic Hospitals Research Centre, Henderson General Hospital, Hamilton, ON, Canada

⁴McMaster University, Department of Clinical Epidemiology and Biostatistics

,

Jeffrey S. Ginsberg

¹Hamilton Civic Hospitals Research Centre, Henderson General Hospital, Hamilton, ON, Canada

³McMaster University, Department of Medicine

› Author Affiliations

Abstract

Summary

To determine whether fibrinolytic testing predicts recurrent venous thrombosis, we have performed a prospective cohort study in which 303 patients with a first episode of venous thromboembolism underwent comprehensive fibrinolytic testing while receiving oral anticoagulants, and after anticoagulants had been discontinued. They were then followed for up to 3 years for recurrent venous thrombosis. No systematic differences in the levels or activity of type 1 plasminogen activator inhibitor (PAI-1), tissue plasminogen activator (tPA) or euglobulin clot lysis times were detected between patients who did, or did not, suffer recurrent thrombosis. There were also no differences in these variables when patients whose initial thrombosis was idiopathic were compared to patients whose thrombosis occurred in the setting of a known thrombotic risk factor. Based on these results, neither measuring fibrinolytic parameters in patients with venous thromboembolism, nor modification of treatment based on the results of such testing, are justified. Our study also confirms that patients with idiopathic venous thromboembolism have a high risk of recurrence.

Keywords

Fibrinolysis - venous thrombosis - recurrent thrombosis - idiopathic venous thromboembolism - predictors

Full Text

References

References
1 Schulman S, Wiman B. The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Duration of Anticoagulation (DURAC) Trial Study Group. Thromb Haemost 1996; 75 (Suppl. 04) 607-11.
2 Levine MN, Hirsh J, Gent M, Turpie AG, Weitz JI, Ginsberg JS, Geerts W, Leclerc J, Neemeh J, Powers P. et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74: 606-11.
3 Levine MN, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M. et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. New England Journal of Medicine 1996; 334 (Suppl. 11) 677-81.
4 The Columbus Investigators.. Low-molecular weight heparin in the treatment of patients with venous thromboembolism. New England Journal of Medicine 1997; 337: 675-62.
5 Hougie C, Williams WJ, Beutler E, Erslev AJ, Lichtman MA. editors. Hematology. Fourth ed. Toronto: McGraw-Hill; 1990: A40 Euglobulin Lysis Time. p. 1774-5.
6 Prins MH, Hirsh J. A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism. Archives of Internal Medicine 1991; 151: 1721-31.